iCrowd Newswire – Sep 18, 2020
The cell line development market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027.
The cell line is an established cell culture, wherein the cells multiply in the apt growth medium and space for growth. Different cell lines are made from different cells. Cell lines enable stepwise alterations in the structure, physiology, and genetic makeup of cells under a customized environment. The cell line development market growth is mainly attributed to increasing adoption of regenerative medicines, rising prevalence of cancer across the globe, and soaring investments in R&D by pharmaceutical and biotechnology companies. Moreover, consistent research in drug discovery activities is further expected to foster market growth during the forecast period. However, the risk of cell line contamination is restricting the market growth.
Request for sample at: https://www.theinsightpartners.com/sample/TIPHE100001196/
North America has been witnessing growing number of COVID-19 cases since the viral outbreak. According to Worldometer, as of September 2, 2020, the number of cases has reached to 6,335,244, with 191,058 deaths, in the US. The pharmaceutical companies and research institution have shifted their research activities in finding vaccine for COVID-19, thereby putting the development of other therapeutics on hold. Moreover, many research organizations are struggling with a wide range of challenges such as reduced funding, cancelled fundraising events, and shelving projects due to economic uncertainty. Thus, the abovementioned factors are hindering the growth of the cell line development market, and the impact is likely to persist for a certain time period.
However, the risks associated with cell line contamination hinder the growth of this market. Merck KGaA, Thermo Fisher Scientific Inc., Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXiAppTec Group are among the leading companies operating in the global cell line development market.
The global cell line development market, based on type, is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest share of the market in 2019. This growth is ascribed to the increasing demand for recombinant cell lines in the production of therapeutic recombinant proteins. However, the hybridomas segment is estimated to register the highest CAGR during the forecast period. This growth is attributed to rising research and development activities for novel biologics.
Stable cell lines are widely used in a wide range application, including biologics production, drug screening, and gene functional studies. The COVID-19 pandemic led to disruptions in all phases of drug development, and it has compelled many pharmaceutical companies and clinical research organizations (CROs) to put their clinical studies on hold. The new government policies, stay-at-home orders, social distancing norms, and widespread anxiety are among the prime challenges faced by researchers conducting the ongoing studies.
The Report Segments Global Cell Line Development Market as Follows:
- Primary Cell Line
- Continuous Cell Lines
- Recombinant Cell Line
- Media & Reagent
- Drug Discovery
- Tissue Engineering
Buy Complete Report at: https://www.theinsightpartners.com/buy/TIPHE100001196/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Keywords: Cell Line Development Market, Cell Line Development